Cargando…
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
Hypoxia, a state of low oxygen, is a common feature of solid tumors and is associated with disease progression as well as resistance to radiotherapy and certain chemotherapeutic drugs. Hypoxic regions in tumors, therefore, represent attractive targets for cancer therapy. To date, five distinct class...
Autores principales: | Guise, Christopher P., Mowday, Alexandra M., Ashoorzadeh, Amir, Yuan, Ran, Lin, Wan-Hua, Wu, Dong-Hai, Smaill, Jeff B., Patterson, Adam V., Ding, Ke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sun Yat-sen University Cancer Center
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935009/ https://www.ncbi.nlm.nih.gov/pubmed/23845143 http://dx.doi.org/10.5732/cjc.012.10285 |
Ejemplares similares
-
Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3
por: Abbattista, Maria R., et al.
Publicado: (2021) -
Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications
por: Ashoorzadeh, Amir, et al.
Publicado: (2022) -
Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
por: van der Wiel, Alexander M.A., et al.
Publicado: (2021) -
Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling
por: Jackson-Patel, Victoria, et al.
Publicado: (2022) -
Antibody-Based Imaging of Bioreductive Prodrug Release
in Hypoxia
por: Tosun, Çağla, et al.
Publicado: (2023)